

INDEX

Section	Title	Page No.
CHAPTER 1: INTRODUCTION		
1.1	Nanotechnology	1
1.2	Metal nanoparticles	3
1.3	Properties of metal nanoparticles	5
	1.3.1 Plasmon resonance in metal nanoparticles	5
	1.3.2 Scattering property of metal nanoparticles	6
	1.3.3 Magnetic properties	6
	1.3.4 Melting point	6
	1.3.5 Mechanical properties	6
1.4	Methods for the synthesis of metal nanoparticles	7
	1.4.1 Polymer stabilized metal nanoparticles	8
1.5	Surface modification and bioconjugation of metal nanoparticles	10
	1.5.1 Surface modification	10
	1.5.2 Bioconjugation	11
1.6	Gold nanoparticles in diagnosis	12
	1.6.1 Biological imaging	12
	1.6.2 X-ray computed topography	13
	1.6.3 Gold nanoparticles as biosensors	14
1.7	Gold nanoparticles in therapy	16
	1.7.1 Historic perspective on the use of gold in medicine	16
	1.7.2 Recent advances on the use of gold nanoparticles in medicine	17
	1.7.2.1 Gold nanoparticles as a heat source	18
	1.7.2.2 Gold nanoparticles for gene therapy	19
	1.7.2.3 Gold nanoparticles for protein and peptide delivery	20
	1.7.2.4 Gold nanoparticles for delivery of drugs	20
1.8	Literature survey	23
	1.8.1 Research articles	23
	1.8.2 Patent status: In the present survey, patents on metal nanoparticles and biologicals are addressed	27
	1.8.3 Status of nanoparticulate systems	29
	Reference	32

Section	Title	Page No.
	CHAPTER 2: GENESIS OF WORK AND OBJECTIVES	39
	CHAPTER 3: ROAD MAP	45
	CHAPTER 4: MATERIALS AND INSTRUMENTS	47
4.1	Materials	47
4.2	Instruments	48
4.3	Software's	48
4.4	Drug profile	49
	4.4.1 Doxorubicin hydrochloride	49
	Polymer profile	51
4.5	4.5.1 Gellan gum	51
	4.5.2 Polyethylene glycol	52
	4.5.3 Sophorolipid	54
CHAPTER 5: SYNTHESIS OF GOLD NANOPARTICLES & TOXICITY OF GOLD NANOPARTICLES		
CHAPTER 5A: SYNTHESIS OF GOLD NANOPARTICLES USING GELLAN GUM AS REDUCING AND STABILIZING AGENT		
5A.1	Outline of the present work	55
	Experimental work	56
	5A.2.1 Synthesis of gellan gum reduced gold nanoparticles	56
	5A.2.2 Preparation of spray dried gold nanoparticles	56
	5A.2.3 Characterization	56
5A.2	5A.2.3.a UV-Visible spectroscopy measurements	56
	5A.2.3.b Transmission electron microscopy	56
	5A.2.3.c X-ray diffraction measurements	56
	5A.2.3.d Zeta potential measurements	57
	5A.2.3.e In vitro stability studies	57
5A.3	Results and discussion	58
CHAPTER 5B: CELLULAR UPTAKE AND IN VIVO ORAL TOXICITY STUDIES OF GELLAN GUM REDUCED GOLD NANOPARTICLES		
5B.1	Outline of the present work	71
	Experimental	73
	5B.2.1 Synthesis and characterization of gellan gum reduced gold nanoparticles	73
5B.2	5B.2.2 Cellular uptake of gold nanoparticles	73
	5B.2.2.a Synthesis of Texas red labeled AuNPs	73
	5B.2.2.b Cell culture and cellular uptake	73
	5B.2.2.c Confocal laser scanning microscopy	74

Section	Title	Page No.
	5.B.2.3 Sub-acute toxicity studies of gold nanoparticles	74
	5B.2.3.a Study design	74
	5B.2.3.b Test animals, housing and feeding conditions	74
	5B.2.3.c Body weight of animals and food intake	74
	5B.2.3.d General observation	75
	5B.2.3.e Dosing of gold nanoparticles to animals	75
	5B.2.3.f Blood assay	75
	Haematology analysis	75
	Biochemical analysis	75
	5B.2.3.g Urine analysis	75
	5B.2.3.h Histopathological observations	76
	5B.2.4 Statistical analysis	76
5B.3	Results and discussion	77
	Reference	98
CHAPTER 6A: DEVELOPMENT OF GELLAN GUM REDUCED GOLD NANOPARTICLES AS A CARRIER FOR DELIVERY OF ANTICANCER DRUG, DOXORUBICIN HYDROCHLORIDE		
6A.1	Outline of the present work	102
6A.2	Experimental work	105
	6A.2.1 Loading of doxorubicin onto gold nanoparticles	105
	6A.2.2 Spray dried doxorubicin gold nanoparticles	105
	6A.2.3 Characterization	106
	6A.2.3.a UV-Vis spectroscopy measurements	106
	6A.2.3.b Transmission electron microscopy	106
	6A.2.3.c Zeta potential measurements	106
	6A.2.3.d pH dependent stability	106
	6A.2.3.e FTIR spectroscopy measurements	106
	6A.2.3.f Fluorescence measurements	106
	6A.2.4 In-vitro cytotoxicity assay on glioma cell lines	107
	6A.2.4.a Cell lines and growth medium	107
	6A.2.4.b Cell preparation	107
	6A.2.4.c Drug addition	107
	6A.2.4.d MTT assay	108
	6A.2.5 Apoptosis studies using confocal microscopy	108
6A.3	Results and discussion	109

Section	Title	Page No.
CHAPTER 6B: DEVELOPMENT AND EVALUATION OF DOXORUBICIN HYDROCHLORIDE LOADED SOPHOROLIPID (SL) POLY (ETHYLENE GLYCOL) (PEG) CNJUGATED GOLD NANOPARTICLES (AuNPs)		
6B.1	Outline of the present work	120
6B.2	Experimental work	122
	6B.2.1 Conjugation of SL and PEG on AuNPs	122
	6B.2.2 Loading of DOX on SL-AuNPs & PEG-SL-AuNPs	122
	6B.2.3 Preparation of spray dried SL-AuNPs, PEG-SL-AuNPs and DOX loaded SL-AuNPs and PEG-SL-AuNPs	122
	6B.2.4 Characterization	123
	6.B.2.4.a UV-Visible spectroscopy measurements	123
	6.B.2.4.b Transmission electron microscopy	123
	6.B.2.4.c Zeta potential measurements	123
	6.B.2.4.d In vitro stability studies	123
	6.B.2.4.e Fluorescence measurements	123
	6B 2.5 In vitro cellular uptake and cytotoxicity assay	124
	6.B.2.5.a Cell lines and growth medium	124
	6.B.2.5.b Synthesis of Texas red labeled SL- AuNPs and PEG-SL-AuNPs	124
	6.B.2.5.c Cell preparation	124
	6.B.2.5.d Samples addition	125
	6.B.2.5.e MTT assay	125
	6B.2.6 Cellular uptake and apoptosis studies using confocal microscopy	126
6B.3	Results and discussion	127
	Reference	147

Section	Title	Page No.
CHAPTER 7: IN-VIVO TUMOR MICROVESSEL DENSITY EVALUATION		
7.1	ANGIOGENESIS: CONCEPT & THERAPEUTICS	154
	7.1.1 Angiogenesis	154
	7.1.2 Tumor Angiogenesis	154
	7.1.3 VEGF as A Prognostic Factor or an Indicator of Angiogenesis	155
	7.1.4 Cyclooxygenase-2 (COX-2) Expression and Angiogenesis	156
	7.1.5 In vitro and In vivo Models to Study Angiogenesis	157
	7.1.6 Modalities for Therapeutic Angiogenesis Inhibition	158
	7.1.6.1 Naturally Occurring Angiogenesis Inhibitors	158
	7.1.6.2 <i>Antagonists of Angiogenic Growth Factors</i>	158
	7.1.6.3 Gene Therapy in Angiogenesis Research	159
	7.1.6.4 Miscellaneous Factors and Conditions	159
	7.1.6.5 Gold Nanoparticles as an Anti-angiogenic property	161
	7.1.6.6 In vivo Anti-tumor Testing	162
	7.1.6.6.1 Establishing Subcutaneous Xenografts	162
	7.1.6.6.2 <i>Assessing The Volume of Subcutaneous Tumors by Caliper Method</i>	163
	7.1.6.6.3 <i>Determination of Therapeutic Effect in Murine Tumor Models</i>	163
7.2	EXPERIMENTAL	164
	7.2.1 Materials	164
	7.2.2 Method	164
	7.2.3 Results & Discussion	165
	7.2.4 In vivo Tumor Growth Inhibition in Mouse Melanoma Model	166
	7.2.4.1 Doxorubicin Gold Nanoparticles	166
	7.2.4.2 Effect of combination drug treatment	167
7.3	References	170
CHAPTER 8: SUMMARY AND CONCLUSION		
8.1	Summary	175
8.2	Conclusion	179
8.3	Scope of future work	180